The Future of Peptide Therapy: Clinical Trials, FDA Pathways, and What Is Moving From Research to Medicine

Peptide therapeutics occupy a growing share of the clinical development pipeline. As of 2024, more than 80 peptide-based drugs have received regulatory approval globally, and several hundred more are in various stages of clinical testing. But the path from bench research to approved medicine is long, expensive, and marked by high attrition. This post examines which peptide candidates are advancing through clinical trials, what FDA regulatory pathways apply, and where the field's trajectory is heading.

The Peptide Register tracks these developments as an independent research reference, cataloguing peptides by mechanism of action, evidence base, and regulatory status across jurisdictions. For background on how regulatory frameworks differ internationally, see the overview of peptide regulation around the world.

Peptide Therapeutics in the Clinical Pipeline

The peptide drug pipeline has expanded significantly in the past decade. Over 150 peptide therapeutics were in active clinical trials as of mid-2024, spanning oncology, metabolic disease, infectious disease, and rare disorders. The success of GLP-1 receptor agonists like semaglutide and tirzepatide has drawn particular attention to peptide-based approaches for metabolic conditions.

Over 150 peptide therapeutics were in active clinical trials globally as of mid-2024. These candidates range from early Phase 1 safety studies to late-stage Phase 3 efficacy trials. Notably, oncology and metabolic disease account for the largest share of peptide clinical trials currently underway. Peptide drug conjugates, which attach cytotoxic agents to peptide targeting sequences, represent one of the fastest-growing subcategories in oncology pipelines.

It is important to note that many peptides discussed in online communities, such as BPC-157 and certain growth hormone secretagogues, remain far from formal approval. BPC-157 has no completed human randomized controlled trials as of early 2025, despite extensive preclinical literature. For a detailed look at what that preclinical evidence actually shows, the Peptide Register maintains a dedicated research profile on BPC-157.

FDA Regulatory Pathways for Peptide Drugs

The FDA regulates peptide therapeutics primarily through the New Drug Application (NDA) and Biologics License Application (BLA) pathways. The FDA classifies most synthetic peptides under 40 amino acids as drugs subject to the NDA pathway. Larger or more complex peptides may fall under the BLA pathway as biological products.

Several expedited pathways can accelerate peptide drug development. Fast Track designation, Breakthrough Therapy designation, Accelerated Approval, and Priority Review each apply to candidates meeting specific criteria, typically involving serious conditions with unmet medical need. Retatrutide, a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, received Fast Track designation from the FDA in 2023 for obesity.

The 505(b)(2) pathway also plays a role, allowing sponsors to reference existing safety and efficacy data for previously approved peptides while seeking approval for new formulations or indications. This pathway has been used for reformulated versions of established peptide drugs.

The Compounding and Grey Market Complication

The regulatory landscape is further complicated by peptide compounding. The FDA's Category 1 and Category 2 lists under the Federal Food, Drug, and Cosmetic Act determine which bulk drug substances can be used by compounding pharmacies. The FDA placed several popular peptides on its Category 1 nomination list, which restricts compounding. This regulatory action has significant implications for patient access and the grey market; the Peptide Register monitors these developments in its grey market tracking section.

The FDA placed semaglutide on its drug shortage list, which temporarily expanded compounding access, but as shortages resolve, compounded versions face renewed restrictions. These regulatory dynamics illustrate the tension between innovation, access, and safety oversight.

What Is Actually Close to Approval

Several peptide candidates are in late-stage trials with realistic near-term approval timelines. Retatrutide completed Phase 2 trials showing significant weight reduction and entered Phase 3 trials in 2024. Tirzepatide, already approved for type 2 diabetes, received FDA approval for obesity in late 2023 under the brand name Zepbound.

Tirzepatide received FDA approval for chronic weight management in November 2023. Meanwhile, oral peptide formulations represent a key area of innovation. Oral semaglutide (Rybelsus) demonstrated that peptide oral bioavailability barriers can be overcome, though absorption remains limited and variable.

It is worth emphasizing what is not close to approval. Many peptides with strong preclinical profiles, including thymosin beta-4, various melanocortin receptor agonists, and numerous growth hormone secretagogues, lack the Phase 2 or Phase 3 human trial data required for regulatory submission. Preclinical promise does not predict clinical success; historically, roughly 90% of drug candidates that enter Phase 1 trials fail to reach approval.

Roughly 90% of drug candidates entering Phase 1 clinical trials historically fail to reach regulatory approval. This attrition rate applies equally to peptide therapeutics. Readers interested in understanding how to critically evaluate the research behind specific peptides can consult the Peptide Register's guide on how to read peptide research.

Looking Ahead

The peptide therapeutics field is expanding in both approved treatments and pipeline candidates. But expansion in research interest should not be confused with expansion in proven clinical utility. The gap between clinical trial activity and regulatory guidance continues to widen, and many popular peptides remain unsupported by human efficacy data. The Peptide Register will continue cataloguing these developments as they unfold, providing structured profiles across our peptide database to support evidence-based evaluation.